Since December 2020, humankind, in an attempt to control the COVID-19 pandemic, experienced the biggest vaccine rollout and immunization process ever remembered. As of May 1, 2021, more than 1 billion doses of a COVID-19 vaccine have been administered worldwide. There are several COVID-19 vaccines available, but only four of them have received emergency use approval by EMA and/or FDA. 1 Ongoing studies are still analyzing their efficacy against the new emerging mutant SARS-CoV2 variants and their safety profile. 2

We present a case of vaccine-induced prothrombotic immune thrombocytopenic (VIPIT) disorder following ChAdOx1 nCoV-19 vaccine in a 29 years old, previously healthy, Caucasian female, which manifested with superior ophthalmic vein (SOV) thrombosis and thrombocytopenia. 3, 4 The patient was referred to our Clinic on March 30, 2021, complaining of severe headache, left orbital swelling, and blurred left eye vision. Initial findings showed thrombocytopenia of 18× 109 per L in association with high D-dimers levels of 35712 μg/L. At physical examination, the patient showed left eyeball swelling with proptosis, limited ocular motility, and diplopia at the vertical gaze (Figure